IMMX
Immix Biopharma, Inc.
There isn't enough reported data to score IMMX yet.
IMMX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
IMMX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
IMMX PE Valuation
IMMX has no meaningful PE right now: it lost money over the past year.
IMMX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect IMMX's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
IMMX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -$0.07 |
| Q2 2026 | -$0.88 | -$0.12 |
| Q1 2026 | -$0.92 | -$0.23 |
| Q4 2025 | -$0.89 | -$0.13 |
| Q3 2025 | -$0.76 | +$0.09 |
| Q2 2025 | -$0.76 | +$0.08 |
| Q1 2025 | -$0.69 | +$0.24 |
| Q4 2024 | -$0.76 | +$0.13 |
IMMX is still losing money, but far less than before: $0.83 per share over the past year, against $3.32 at its worst in late 2022.
IMMX Quarterly Revenue
IMMX's revenue is shrinking: $0 last quarter.
IMMX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$12.4M | -$6.2M |
| Q2 2026 | -$11.8M | -$6.3M |
| Q1 2026 | -$9.9M | -$8.1M |
| Q4 2025 | -$11.2M | -$9.2M |
| Q3 2025 | -$6.3M | -$2M |
| Q2 2025 | -$5.4M | -$84.4K |
| Q1 2025 | -$1.8M | +$2.4M |
| Q4 2024 | -$2M | +$707.3K |
IMMX has burned cash in almost every quarter: −$45M over the past year, against −$15M the year before.
IMMX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +10.3M shares |
| 1 year | +147% | +44.1M shares |
| 3 years | +433% | +60.2M shares |
| 5 years | +744% | +65.3M shares |
| Available history | +2095% | +70.7M shares |
IMMX has 74M diluted shares, up 147% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | $44,000 |
| Q3 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
IMMX Net Leverage
IMMX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IMMX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.9 | Neutral |
| Stochastic | 8.4 | Oversold |
IMMX's weekly RSI is 43 (neutral) and its Stochastic is 8 (oversold).
IMMX PE vs Healthcare Sector
IMMX has no meaningful PE right now: it lost money over the past year.
IMMX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.76 | 7.9% below |
| 20 week MA | $10.3 | 21% below |
| 50 week MA | $8.85 | 8.8% below |
| 100 week MA | $5.60 | 44% above |
| 200 week MA | $4.15 | 94% above |
IMMX has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 94% above its 200-week average.
IMMX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $4.00 | $2.95 | -26% |
| 2022 | $2.95 | $2.17 | -26% |
| 2023 | $2.17 | $6.92 | +219% |
| 2024 | $6.92 | $2.24 | -68% |
| 2025 | $2.24 | $5.64 | +152% |
| 2026 YTD | $5.64 | $8.07 | +43% |
IMMX's yearly returns have swung widely, from +219% in 2023 to −68% in 2024. It's up 43% so far in 2026.